2023 was a blockbuster year for Mayo Clinic spinoff Pneumeric. After its Capnospot device for treating collapsed lungs earned FDA approval in March, the company landed $2.2 million from investors this past summer. Dr. Johnathon Aho aims to build on that momentum to ramp up commercial sales of the device in 2024. He’s primarily selling to EMS and firefighting organizations, though hospitals are a potential market, too. Aho, with more than 20 patents under his belt, believes that Capnospot will become the standard of care for treating tension pneumothorax, a type of collapsed lung that can be fatal.

Return to TCB 100 for 2024